Factors to consider when selecting patients with multiple myeloma for treatment with bispecifics

Factors to consider when selecting patients with multiple myeloma for treatment with bispecifics

00:41 |

Related Videos

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

5:11

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

3:08

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

Frontline treatment for CLL: the changing paradigm

1:31

Frontline treatment for CLL: the changing paradigm

The use of outpatient cilta-cel in the treatment of multiple myeloma

1:36

The use of outpatient cilta-cel in the treatment of multiple myeloma

Early detection and interception across hematological cancers

0:44

Early detection and interception across hematological cancers

Trials of interest in newly diagnosed myeloma presented at IMS 2024

3:48

Trials of interest in newly diagnosed myeloma presented at IMS 2024

The tests that are needed to make a definitive diagnosis of CLL

2:59

The tests that are needed to make a definitive diagnosis of CLL

Treatment-free remission after second-generation TKI treatment in CML

1:01

Treatment-free remission after second-generation TKI treatment in CML

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

1:38

The use of golcadomide in combination with R-CHOP for the treatment of aggressive B-cell lymphomas

Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions

1:25

Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions

The future of CLL treatment: aiming for long-lasting remission

1:42

The future of CLL treatment: aiming for long-lasting remission

Master class in transplantation and hematology: highlights

3:40

Master class in transplantation and hematology: highlights

Mechanisms of resistance to the TKI asciminib in CML

1:16

Mechanisms of resistance to the TKI asciminib in CML

Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics

1:14

Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

5:21

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

Molecular MRD as a prognostic marker for AML patients with mutated CEBPA

1:13

Molecular MRD as a prognostic marker for AML patients with mutated CEBPA

Challenges in developing immunotherapies for CLL compared to other hematologic malignancies

1:53

Challenges in developing immunotherapies for CLL compared to other hematologic malignancies

Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusion

1:55

Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusion

The new criteria for defining high-risk multiple myeloma

3:00

The new criteria for defining high-risk multiple myeloma

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

2:55

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib